Featured Story

Nanoparticle coating spurs oral cancer vaccine potential

The stomach and the gut are difficult places for DNA to survive and eventually pass into the bloodstream intact. Now researchers have developed nanoparticle-coated bacteria that can someday be used to create effective DNA vaccines.

J&J banking on improved insulin delivery tech to cure diabetes business woes

Johnson & Johnson's diabetes care business experienced a year-over-year revenue decline of 2.2% in 2015 and fell 8.7% for the year. But J&J executives are optimistic about a turnaround, citing the recent launch of the drug-delivering Animas Vibe continuous glucose monitor and insulin pump, and longer term plans for a wearable insulin pump.

Mersana's cancer-fighting antibody-drug conjugate shows promise in animal studies

Fierce 15 member Mersana Therapeutics, a developer of customizable next-generation antibody-drug conjugates, announced that its lead anticancer candidate showed promise in preclinical studies.

'Doc fix' reform bill alters Medicare reimbursement for some oral-only meds

The elimination of the Medicare Sustained Growth Rate formula that threatened large Medicare reimbursement cuts to doctors on an annual basis is the most significant entitlement reform achieved by the new Congress.

Columbia Labs picks up multidrug intravaginal ring created at MIT and MGH

Under the guidance of drug delivery guru Dr. Robert Langer of MIT and Massachusetts General Hospital's Dr. William Crowley, Boston's Columbia Laboratories has acquired the license to an intravaginal ring designed to deliver several different drugs at a time.


From Our Sister Sites


Neuronetics has closed a $34.3 million Series F round to further commercialize its NeuroStar transcranial magnetic stimulation (TMS) therapy system to treat drug-resistant major depressive disorder (MDD), as well as to fund a registration study for adolescent use of the device. NeuroStar was cleared by FDA in 2008 to treat MDD, but the company said it's just recently been gaining traction with payers.  


The world's top sellers of the world's top biologic meds haven't changed much in the last few years. Ranked by 2014 sales, it's your usual suspects--Roche, Amgen, Novo Nordisk, AbbVie. But as PMLiVE notes in its annual ranking, times are a-changing.